Skip header and navigation

Refine By

1500 records – page 1 of 150.

A 1-year, placebo-controlled, double-blind house-dust-mite immunotherapy study in asthmatic adults.

https://arctichealth.org/en/permalink/ahliterature15782
Source
Allergy. 1997 Aug;52(8):853-9
Publication Type
Article
Date
Aug-1997
Author
O T Olsen
K R Larsen
L. Jacobsan
U G Svendsen
Author Affiliation
Department of Pulmonery Medicine and Allergology, Gentofte Hospital, University of Copenhagen, Hellerup, Denmark.
Source
Allergy. 1997 Aug;52(8):853-9
Date
Aug-1997
Language
English
Publication Type
Article
Keywords
Adolescent
Adrenergic beta-Agonists - therapeutic use
Adult
Antigens, Dermatophagoides
Asthma - diagnosis - drug therapy - therapy
Bronchial Provocation Tests
Double-Blind Method
Female
Forced expiratory volume
Glycoproteins - administration & dosage - adverse effects - immunology
Humans
Immunoglobulin E - analysis - blood - immunology
Immunotherapy
Male
Middle Aged
Peak Expiratory Flow Rate
Severity of Illness Index
Skin Tests
Steroids - therapeutic use
Vital Capacity
Abstract
Thirty-one adult patients with asthma caused by house-dust mites (HDM) were included in this placebo-controlled, double-blind study to evaluate the efficacy and safety of specific immunotherapy (SIT) with biologically standardized extracts of HDM. The specific diagnosis was confirmed by skin prick tests, specific IgE, and bronchial provocation tests with HDM allergens. The patients were randomized to receive active treatment with extracts of either Dermatophagoides pteronyssinus (Dpt) or D. farinae (Dfa) (Alutard SQ, ALK, Denmark) or placebo injections. Twenty-three patients completed the study. After 1 year of treatment, we found a clinically important and significant reduction in both asthma medicine consumption (inhaled steroids 38% and beta 2-agonists 46%) and symptom score (57%) in the actively treated group, but not the placebo group. These findings were confirmed by a significant decrease in skin and bronchial sensitivity to HDM in the active group. Additionally, there was a significant difference in the patients' scores for effect in favor of the actively treated group. Total IgE and specific IgE to HDM showed no significant changes before and after treatment for either group. Spirometric lung-function measurements showed a significant increase in forced expiratory volume in 1 s (FEV1) from 85% before to 89% of predicted values after treatment for the actively treated group. Peak-flow measurements at home showed no significant changes during the study. It is concluded that allergen SIT is an effective treatment in adult patients suffering from asthma due to HDM.
PubMed ID
9284985 View in PubMed
Less detail

A 2 year multidomain intervention of diet, exercise, cognitive training, and vascular risk monitoring versus control to prevent cognitive decline in at-risk elderly people (FINGER): a randomised controlled trial.

https://arctichealth.org/en/permalink/ahliterature264224
Source
Lancet. 2015 Jun 6;385(9984):2255-63
Publication Type
Article
Date
Jun-6-2015
Author
Tiia Ngandu
Jenni Lehtisalo
Alina Solomon
Esko Levälahti
Satu Ahtiluoto
Riitta Antikainen
Lars Bäckman
Tuomo Hänninen
Antti Jula
Tiina Laatikainen
Jaana Lindström
Francesca Mangialasche
Teemu Paajanen
Satu Pajala
Markku Peltonen
Rainer Rauramaa
Anna Stigsdotter-Neely
Timo Strandberg
Jaakko Tuomilehto
Hilkka Soininen
Miia Kivipelto
Source
Lancet. 2015 Jun 6;385(9984):2255-63
Date
Jun-6-2015
Language
English
Publication Type
Article
Keywords
Aged
Cognition Disorders - epidemiology - prevention & control
Diet
Double-Blind Method
Exercise
Exercise Therapy
Humans
Male
Middle Aged
Neuropsychological Tests
Risk assessment
Vascular Diseases - epidemiology - prevention & control
Abstract
Modifiable vascular and lifestyle-related risk factors have been associated with dementia risk in observational studies. In the Finnish Geriatric Intervention Study to Prevent Cognitive Impairment and Disability (FINGER), a proof-of-concept randomised controlled trial, we aimed to assess a multidomain approach to prevent cognitive decline in at-risk elderly people from the general population.
In a double-blind randomised controlled trial we enrolled individuals aged 60-77 years recruited from previous national surveys. Inclusion criteria were CAIDE (Cardiovascular Risk Factors, Aging and Dementia) Dementia Risk Score of at least 6 points and cognition at mean level or slightly lower than expected for age. We randomly assigned participants in a 1:1 ratio to a 2 year multidomain intervention (diet, exercise, cognitive training, vascular risk monitoring), or a control group (general health advice). Computer-generated allocation was done in blocks of four (two individuals randomly allocated to each group) at each site. Group allocation was not actively disclosed to participants and outcome assessors were masked to group allocation. The primary outcome was change in cognition as measured through comprehensive neuropsychological test battery (NTB) Z score. Analysis was by modified intention to treat (all participants with at least one post-baseline observation). This trial is registered at ClinicalTrials.gov, number NCT01041989.
Between Sept 7, 2009, and Nov 24, 2011, we screened 2654 individuals and randomly assigned 1260 to the intervention group (n=631) or control group (n=629). 591 (94%) participants in the intervention group and 599 (95%) in the control group had at least one post-baseline assessment and were included in the modified intention-to-treat analysis. Estimated mean change in NTB total Z score at 2 years was 0·20 (SE 0·02, SD 0·51) in the intervention group and 0·16 (0·01, 0·51) in the control group. Between-group difference in the change of NTB total score per year was 0·022 (95% CI 0·002-0·042, p=0·030). 153 (12%) individuals dropped out overall. Adverse events occurred in 46 (7%) participants in the intervention group compared with six (1%) participants in the control group; the most common adverse event was musculoskeletal pain (32 [5%] individuals for intervention vs no individuals for control).
Findings from this large, long-term, randomised controlled trial suggest that a multidomain intervention could improve or maintain cognitive functioning in at-risk elderly people from the general population.
Academy of Finland, La Carita Foundation, Alzheimer Association, Alzheimer's Research and Prevention Foundation, Juho Vainio Foundation, Novo Nordisk Foundation, Finnish Social Insurance Institution, Ministry of Education and Culture, Salama bint Hamdan Al Nahyan Foundation, Axa Research Fund, EVO funding for University Hospitals of Kuopio, Oulu, and Turku and for Seinäjoki Central Hospital and Oulu City Hospital, Swedish Research Council, Swedish Research Council for Health, Working Life and Welfare, and af Jochnick Foundation.
Notes
Comment In: Nat Rev Neurol. 2015 May;11(5):24825799934
PubMed ID
25771249 View in PubMed
Less detail

A 3-month evaluation of the efficacy of nedocromil sodium in asthma: a randomized, double-blind, placebo-controlled trial of nedocromil sodium conducted by a Canadian multicenter study group.

https://arctichealth.org/en/permalink/ahliterature229565
Source
J Allergy Clin Immunol. 1990 Mar;85(3):612-7
Publication Type
Article
Date
Mar-1990
Author
A S Rebuck
S. Kesten
L P Boulet
A. Cartier
D. Cockcroft
J. Gruber
F. Laberge
E. Lee-Chuy
M. Keshmiri
G F MacDonald
Author Affiliation
Edmonton General Hospital, Canada.
Source
J Allergy Clin Immunol. 1990 Mar;85(3):612-7
Date
Mar-1990
Language
English
Publication Type
Article
Keywords
Adult
Anti-Inflammatory Agents, Non-Steroidal - adverse effects - therapeutic use
Asthma - drug therapy - physiopathology
Canada
Chronic Disease
Double-Blind Method
Drug Therapy, Combination
Drug Tolerance
Female
Humans
Male
Middle Aged
Multicenter Studies as Topic
Nedocromil
Peak Expiratory Flow Rate - drug effects - physiology
Quinolones - adverse effects - therapeutic use
Randomized Controlled Trials as Topic
Time Factors
Abstract
Nedocromil sodium is a pyranoquinoline dicarboxylic acid derivative, formulated in a metered-dose inhaler. Because nedocromil sodium has in vitro and in vivo anti-inflammatory properties, it was evaluated in a group of steroid-dependent patients with asthma to observe how well it might be tolerated and for evidence of any beneficial effects. In a double-blind, group-comparative study, 127 patients received nedocromil sodium and 61 received placebo, administered as two puffs of 2 mg, four times per day, for 12 weeks. Ten patients developed adverse reactions, seven receiving active drug and three patients receiving placebo. Two patients of each group withdrew because of worsening asthma. Despite selecting patients whose asthma was stable, when they were receiving established therapeutic regimens that included steroids and bronchodilators, it was found that diary-card symptom scores, morning and evening peak expiratory flow rate values, and inhaled beta-agonist usage all demonstrated slight but significant benefit with addition of nedocromil sodium. It is concluded that the inhaled, anti-inflammatory agent, nedocromil sodium, may be added to asthma-treatment regimens with the reasonable expectation of further modest symptomatic benefit.
PubMed ID
2155958 View in PubMed
Less detail

3-year follow-up of patients randomised in the metoprolol in dilated cardiomyopathy trial. The Metoprolol in Dilated Cardiomyopathy (MDC) Trial Study Group.

https://arctichealth.org/en/permalink/ahliterature10861
Source
Lancet. 1998 Apr 18;351(9110):1180-1
Publication Type
Article
Date
Apr-18-1998

5-Aminosalicylic acid enemas in treatment of distal ulcerative colitis and proctitis in Canada.

https://arctichealth.org/en/permalink/ahliterature234423
Source
Dig Dis Sci. 1987 Dec;32(12 Suppl):64S-66S
Publication Type
Article
Date
Dec-1987
Author
L R Sutherland
F. Martin
Author Affiliation
Department of Gastroenterology, University of Calgary, Canada.
Source
Dig Dis Sci. 1987 Dec;32(12 Suppl):64S-66S
Date
Dec-1987
Language
English
Publication Type
Article
Keywords
Adult
Aminosalicylic Acids - administration & dosage - therapeutic use
Canada
Clinical Trials as Topic
Colitis, Ulcerative - drug therapy
Double-Blind Method
Enema
Female
Humans
Male
Mesalamine
Proctitis - drug therapy
Random Allocation
Time Factors
Abstract
The efficacy and safety of 4 g 5-aminosalicylic acid (5-ASA) enemas were assessed in 59 patients with ulcerative colitis involving up to 50 cm of their distal colon. Twenty-nine patients received 5-ASA and 30 received a placebo. There were 12 dropouts (five in the active and seven in the placebo group) during the study because of insufficient efficacy. After six weeks of therapy, 63% of the patients receiving the 5-ASA were considered to be "much improved" by the study physician compared to 20% patients on placebo (P less than 0.0001). A disease activity index (DAI), based upon patient symptoms and sigmoidoscopic appearance, was used to assess efficacy. Mean DAI declined 75% for patients on 5-ASA enemas and 32% for patients on placebo (P less than 0.05). The 5-ASA enemas are well tolerated and are of benefit in the treatment of ulcerative colitis confined to the distal colon.
PubMed ID
3319459 View in PubMed
Less detail

A 6-month, randomized, double-masked comparison of latanoprost with timolol in patients with open angle glaucoma or ocular hypertension.

https://arctichealth.org/en/permalink/ahliterature212248
Source
Acta Ophthalmol Scand. 1996 Apr;74(2):140-4
Publication Type
Article
Date
Apr-1996
Author
B. Friström
Author Affiliation
Department of Ophthalmology, University of Linköping, Sweden.
Source
Acta Ophthalmol Scand. 1996 Apr;74(2):140-4
Date
Apr-1996
Language
English
Publication Type
Article
Keywords
Adrenergic beta-Antagonists - administration & dosage - adverse effects - therapeutic use
Adult
Aged
Aged, 80 and over
Double-Blind Method
Female
Follow-Up Studies
Glaucoma, Open-Angle - drug therapy - physiopathology
Humans
Intraocular Pressure - drug effects
Male
Middle Aged
Ocular Hypertension - drug therapy - physiopathology
Ophthalmic Solutions
Prostaglandins F, Synthetic - administration & dosage - adverse effects - therapeutic use
Safety
Scandinavia
Timolol - administration & dosage - adverse effects - therapeutic use
Abstract
The intraocular pressure reducing effect and side-effects of latanoprost, a phenyl-substituted prostaglandin analogue, were compared with those of timolol, in a group of 31 glaucomatous or ocular hypertensive patients, divided into three subgroups. The study was randomized and double masked. At the end of 6 month's treatment with latanoprost 0.005% once daily, either as a morning dose or as an evening dose, there was a reduction in intraocular pressure of 33% (p
PubMed ID
8739678 View in PubMed
Less detail

A 15-month evaluation of the effects of repeated subgingival minocycline in chronic adult periodontitis.

https://arctichealth.org/en/permalink/ahliterature201582
Source
J Periodontol. 1999 Jun;70(6):657-67
Publication Type
Article
Date
Jun-1999
Author
D. van Steenberghe
B. Rosling
P O Söder
R G Landry
U. van der Velden
M F Timmerman
E F McCarthy
G. Vandenhoven
C. Wouters
M. Wilson
J. Matthews
H N Newman
Author Affiliation
Catholic University, Leuven, Belgium.
Source
J Periodontol. 1999 Jun;70(6):657-67
Date
Jun-1999
Language
English
Publication Type
Article
Keywords
Adult
Aggregatibacter actinomycetemcomitans - drug effects
Analysis of Variance
Anti-Bacterial Agents - administration & dosage
Campylobacter - drug effects
Canada
Chronic Disease
Colony Count, Microbial
Dental Plaque Index
Dental Scaling
Double-Blind Method
Eikenella corrodens - drug effects
Europe
Female
Fusobacterium nucleatum - drug effects
Humans
Longitudinal Studies
Male
Middle Aged
Minocycline - administration & dosage
Ointments
Periodontal Index
Periodontal Pocket - drug therapy - microbiology
Periodontitis - drug therapy - microbiology
Porphyromonas gingivalis - drug effects
Prevotella intermedia - drug effects
Statistics, nonparametric
Treatment Outcome
Treponema - drug effects
Abstract
A double-blind, randomized, parallel, comparative study was designed to evaluate the long-term safety and efficacy of subgingivally administered minocycline ointment versus a vehicle control.
One hundred four patients (104) with moderate to severe adult periodontitis (34 to 64 years of age; mean 46 years) were enrolled in the study. Following scaling and root planing, patients were randomized to receive either 2% minocycline ointment or a matched vehicle control. Study medication was administered directly into the periodontal pocket with a specially designed, graduated, disposable applicator at baseline; week 2; and at months 1, 3, 6, 9, and 12. Scaling and root planing was repeated at months 6 and 12. Standard clinical variables (including probing depth and attachment level) were evaluated at baseline and at months 1, 3, 6, 9, 12, and 15. Microbiological sampling using DNA probes was done at baseline; at week 2; and at months 1, 3, 6, 9, 12, and 15.
Both treatment groups showed significant and clinically relevant reductions in the numbers of each of the 7 microorganisms measured during the entire 15-month study period. When differences were detected, sites treated with minocycline ointment always produced statistically significantly greater reductions than sites which received the vehicle control. For initial pockets > or =5 mm, a mean reduction in probing depth of 1.9 mm was seen in the test sites, versus 1.2 mm in the control sites. Sites with a baseline probing depth > or =7 mm and bleeding index >2 showed an average of 2.5 mm reduction with minocycline versus 1.5 mm with the vehicle. Gains in attachment (0.9 mm and 1.1 mm) were observed in minocycline-treated sites, with baseline probing depth > or =5 mm and > or =7 mm, respectively, compared with 0.5 mm and 0.7 mm gain at control sites. Subgingival administration of minocycline ointment was well tolerated.
Overall, the results demonstrate that repeated subgingival administration of minocycline ointment in the treatment of adult periodontitis is safe and leads to significant adjunctive improvement after subgingival instrumentation in both clinical and microbiologic variables over a 15-month period.
PubMed ID
10397521 View in PubMed
Less detail

250 microg or 500 microg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study.

https://arctichealth.org/en/permalink/ahliterature148735
Source
Lancet Neurol. 2009 Oct;8(10):889-97
Publication Type
Article
Date
Oct-2009
Author
Paul O'Connor
Massimo Filippi
Barry Arnason
Giancarlo Comi
Stuart Cook
Douglas Goodin
Hans-Peter Hartung
Douglas Jeffery
Ludwig Kappos
Francis Boateng
Vitali Filippov
Maria Groth
Volker Knappertz
Christian Kraus
Rupert Sandbrink
Christoph Pohl
Timon Bogumil
P. O'Connor
M. Filippi
B. Arnason
S. Cook
D. Goodin
H-P Hartung
H-P Harung
L. Kappos
D. Jeffery
G. Comi
Author Affiliation
St Michael's Hospital, Toronto, Canada. oconnorp@smh.toronto.on.ca
Source
Lancet Neurol. 2009 Oct;8(10):889-97
Date
Oct-2009
Language
English
Publication Type
Article
Keywords
Adolescent
Adult
Brain - drug effects - pathology
Dose-Response Relationship, Drug
Double-Blind Method
Female
Humans
Immunologic Factors - therapeutic use
Interferon-beta - administration & dosage
Magnetic Resonance Imaging
Male
Middle Aged
Multiple Sclerosis, Relapsing-Remitting - drug therapy - pathology
Peptides - therapeutic use
Young Adult
Abstract
The aim of the Betaferon Efficacy Yielding Outcomes of a New Dose (BEYOND) trial was to compare the efficacy, safety, and tolerability of 250 microg or 500 microg interferon beta-1b with glatiramer acetate for treating relapsing-remitting multiple sclerosis.
Between November, 2003, and June, 2005, 2447 patients with relapsing-remitting multiple sclerosis were screened and 2244 patients were enrolled in this prospective, multicentre, randomised trial. Patients were randomly assigned 2:2:1 by block randomisation with regional stratification to receive one of two doses of interferon beta-1b (250 microg or 500 microg) subcutaneously every other day or 20 mg glatiramer acetate subcutaneously every day. The primary outcome was relapse risk, defined as new or recurrent neurological symptoms separated by at least 30 days from the preceding event and that lasted at least 24 h. Secondary outcomes were progression on the expanded disability status scale (EDSS) and change in T1-hypointense lesion volume. Clinical outcomes were assessed quarterly for 2.0-3.5 years; MRI was done at screening and annually thereafter. Analysis was by per protocol. This study is registered, number NCT00099502.
We found no differences in relapse risk, EDSS progression, T1-hypointense lesion volume, or normalised brain volume among treatment groups. Flu-like symptoms were more common in patients treated with interferon beta-1b (p
Notes
Comment In: Lancet Neurol. 2009 Dec;8(12):1085-6; author reply 1086-719909906
Comment In: Lancet Neurol. 2009 Oct;8(10):870-119729345
Erratum In: Lancet Neurol. 2012 Jan;11(1):27Cree, B [added]; Harung, H-P [corrected to Hartung, H-P]
Erratum In: Lancet Neurol. 2009 Nov;8(11):981
Erratum In: Lancet Neurol. 2011 Feb;10(2):115
PubMed ID
19729344 View in PubMed
Less detail

Abortion induced with methotrexate and misoprostol: a comparison of various protocols.

https://arctichealth.org/en/permalink/ahliterature209155
Source
Contraception. 1997 Mar;55(3):159-63
Publication Type
Article
Date
Mar-1997
Author
E R Wiebe
Author Affiliation
Department of Family Practice, University of British Colubmia, Vancouver, Canada.
Source
Contraception. 1997 Mar;55(3):159-63
Date
Mar-1997
Language
English
Publication Type
Article
Keywords
Abortifacient Agents, Nonsteroidal - administration & dosage
Abortion, Induced - methods - statistics & numerical data
Administration, Intravaginal
Administration, Oral
Adult
Canada
Cohort Studies
Dose-Response Relationship, Drug
Double-Blind Method
Female
Humans
Injections, Intramuscular
Methotrexate - administration & dosage
Misoprostol - administration & dosage
Patient Acceptance of Health Care
Pregnancy
Pregnancy Trimester, First
Time Factors
Urban Population
Abstract
Seven hundred fifty-six women had abortions induced with methotrexate and misoprostol. Various protocols were compared. In Group 1, phase 1, after receiving 50 mg/m2 methotrexate IM, 289 women were randomized to receive either 750 or 500 micrograms of vaginal misoprostol. In Group 1, phase 2, 84 women who had failed to abort after one dose of misoprostol were randomized to receive either vaginal or oral routes for the second dose of misoprostol given on Day 8. In Group 2, a cohort of 226 women who received 60 mg/m2 methotrexate were compared to the 289 women who received 50 mg/m2 in Group 1. There were no differences in rates of effectiveness in the various trial groups. Side effects were greater with 60 mg/m2 of methotrexate. In Group 3, a cohort of 241 women received the misoprostol in three vaginal doses 8 hr apart starting on Day 5, and were compared to the 289 women in Group 1 receiving one vaginal dose. In women whose medical abortion failed, fetuses were found to have limb abnormalities In the total group of 756 women, 88.8% aborted successfully without surgical aspiration, with only minor side effects, and the acceptance rate was high. This study indicates that medical abortions induced with methotrexate and misoprostol are safe and effective, but more research is needed to find a more effective protocol.
PubMed ID
9115004 View in PubMed
Less detail

Absence of effect on exercise capacity of 12-weeks treatment with ramipril in patients with moderate congestive heart failure. Ramipril Study Group.

https://arctichealth.org/en/permalink/ahliterature50173
Source
Eur Heart J. 1994 Dec;15(12):1659-65
Publication Type
Article
Date
Dec-1994
Author
T. Gundersen
K. Swedberg
O. Amtorp
J. Remes
B. Nilsson
Author Affiliation
Medical Department, Aust-Agder Central Hospital, Arendal, Norway.
Source
Eur Heart J. 1994 Dec;15(12):1659-65
Date
Dec-1994
Language
English
Publication Type
Article
Keywords
Cardiac Output, Low - drug therapy
Double-Blind Method
Exercise Test
Heart Failure, Congestive - drug therapy
Humans
Ramipril - therapeutic use
Research Support, Non-U.S. Gov't
Treatment Outcome
Abstract
Pharmacological therapy in cases of chronic congestive heart failure (CHF) is usually evaluated by maximal exercise time. To assess the effect of an angiotensin converting enzyme inhibitor, ramipril, 223 patients with moderate CHF were studied in 24 centres in four Nordic countries in a randomized, double-blind, placebo-controlled, parallel group design. The study drug was titrated from 1.25 mg to a maximum of 10 mg once daily (o.d) over a period of 4 weeks (mean dose 8 mg). A symptom-limited bicycle exercise test, starting at 30 watts and increasing by 10 watts.min-1, was used to evaluate exercise capacity. Reproducible tests were required at baseline, and the test was repeated after 4, 8 and 12 weeks of treatment. Seven deaths were recorded in the placebo group and one death in the ramipril group. A total of 195 patients completed 12 weeks of treatment (placebo group n = 91, ramipril group n = 104). The groups had similar baseline characteristics. Maximal exercise time was increased by mean (SD) 35 s (9) and 41 s (8) in the placebo and ramipril groups, respectively. The adjusted difference between the groups at 12 weeks was 9 s (12) (ns). A significant decrease in blood pressure and rate-pressure product at rest and at end of exercise was obtained by ramipril as compared with placebo. Significantly fewer patients deteriorated in NYHA class from baseline to 12 weeks of ramipril treatment compared to placebo (P = 0.012). Concomitant medication for CHF increased significantly in the placebo group as compared with ramipril-treated patients (P = 0.003).(ABSTRACT TRUNCATED AT 250 WORDS)
PubMed ID
7698136 View in PubMed
Less detail

1500 records – page 1 of 150.